Does the Implementation of Nurse-driven HIV Screening for Key Populations in the Emergency Departments Limit Undiagnosed Infections in the Paris Metropolitan Area? DEPIST Trial (ANRS 14055) (DEPIST)
Primary Purpose
Hiv, Nurse's Role
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Nurse-driven HIV screening for key populations combined with usual physician-directed diagnostic testing
Physician-directed diagnostic testing
Sponsored by
About this trial
This is an interventional screening trial for Hiv focused on measuring Emergency service, Hospital, HIV, Mass screening, Nurses, Prevention and control, Key populations, Targeted screening
Eligibility Criteria
Inclusion Criteria:
- Patients aged 18 to 64 years and visiting a participating ED for reasons other than a potential exposure to HIV within less than 48 hours
Exclusion Criteria:
- Not applicable
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Nurse-driven HIV screening for key populations+UD
Physician-directed diagnostic testing alone
Arm Description
Nurse-driven HIV screening for key populations combined with usual physician-directed diagnostic testing (UD)
Outcomes
Primary Outcome Measures
Proportion of new HIV diagnoses among included patients.
Secondary Outcome Measures
Feasibility of the screening strategy and its implementation
Feasibility of the screening strategy and its implementation based on:
proportion of distributed and completed self-administered questionnaires among the patients included and among the patients able to participate who were not known to be HIV positive,
the proportion of rapid tests offered by nurses among patients belonging to key populations,
the proportion of patients screened by nurses among patients who were offered a rapid test and among patients belonging to high-risk groups .
Effectiveness of the screening processes used by the caregivers, particularly the integration of the electronic questionnaire, and used by the patients as well as acceptability
Proportions of patients with a new diagnosis
Proportions of patients with a new diagnosis who had:
a follow up visit with an infectious disease specialist within 1 month,
a CD4 cell count greater or equal to 500 or 350/µL and no HIV-related symptoms,
an acute HIV infection.
Estimation through modelling of the number of new HIV diagnoses for different levels of coverage of the screening strategy in the Paris metropolitan area.
Full Information
NCT ID
NCT04298801
First Posted
March 4, 2020
Last Updated
March 4, 2020
Sponsor
Assistance Publique - Hôpitaux de Paris
1. Study Identification
Unique Protocol Identification Number
NCT04298801
Brief Title
Does the Implementation of Nurse-driven HIV Screening for Key Populations in the Emergency Departments Limit Undiagnosed Infections in the Paris Metropolitan Area? DEPIST Trial (ANRS 14055)
Acronym
DEPIST
Official Title
Does the Implementation of Nurse-driven HIV Screening for Key Populations in the Emergency Departments Limit Undiagnosed Infections in the Paris Metropolitan Area?
Study Type
Interventional
2. Study Status
Record Verification Date
March 2020
Overall Recruitment Status
Unknown status
Study Start Date
June 2020 (Anticipated)
Primary Completion Date
June 2021 (Anticipated)
Study Completion Date
June 2021 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
In France, 40% of newly diagnosed HIV infections are concentrated in the Paris metropolitan area.
Two key populations are mainly concerned: persons born in a foreign country and men who have sex with men. The randomized trial ANRS DICI-VIH (2014-2015) showed that nurse-driven HIV screening for key populations, supported by research staff, in 8 emergency departments (EDs) of the region, was effective in addition to diagnostic testing. The strategy advocated by the WHO and the recent French recommendations support the proposal of screening for key populations in the EDs. Thus, it is important to evaluate the impact and the feasibility of the implementation of this strategy on a large scale.
The aim is to evaluate the impact of a wide implementation of nurse-driven HIV screening by rapid test in key populations combined with usual physician-directed diagnostic testing (intervention strategy) compared to diagnostic testing alone (control strategy) in the usual practice of the EDs.
The strategies will be compared during two periods in 18 EDs of Paris metropolitan area following a stepped-wedge cluster randomized trial.
During intervention period, nurses will suggest performing an HIV rapid test to patients belonging to key populations according to the answers to a self-administered questionnaire.
Detailed Description
Background:
In France, 40% of newly diagnosed HIV infections are concentrated in the Paris metropolitan area.
Two key populations are mainly concerned: persons born in a foreign country and men who have sex with men. The randomized trial ANRS DICI-VIH (2014-2015) showed that nurse-driven HIV screening for key populations, supported by research staff, in 8 emergency departments (EDs) of the region, was effective in addition to diagnostic testing. The strategy advocated by the WHO and the recent French recommendations of the National Health Authority (HAS) and expert group support the proposal of screening for key populations in the EDs. Thus, it is important to evaluate the impact and the feasibility of the implementation of this strategy on a large scale in a context where local institutions are taking initiatives to curb the epidemic ("Pour une Ile-de-France sans sida", "Vers Paris sans sida").
Our hypothesis is that nurse-driven HIV screening for key populations can be integrated to the consultants' care pathway as usual practice of the ED and assured over the long term in the Paris metropolitan area; this strategy combined with physician-directed diagnostic testing could reduce undiagnosed infections and help control the epidemic.
Primary objective:
The primary objective is to evaluate the impact of a wide implementation of nurse-driven HIV screening by rapid test in key populations combined with usual physician-directed diagnostic testing (intervention strategy) compared to diagnostic testing alone (control strategy) in the usual practice of the EDs.
Patients aged 18 to 64 years and visiting a participating ED for reasons other than a potential exposure to HIV within less than 48 hours will be included.
The primary outcome is the proportion of new HIV diagnoses among included patients.
Secondary objectives are to :
evaluate the feasibility of nurse-driven screening and its long-term implementation,
evaluate the effectiveness of the screening process used by the caregivers, particularly the use of an electronic questionnaire, and by the patients as well as the acceptability,
compare newly diagnosed HIV+ patients in the two groups in terms of :
linkage to follow up care,
proportions of patients who had a CD4 cell count greater or equal to 500 or 350 cells/µL and no HIV-related symptoms and proportions of patients with acute HIV infection.
estimate through modelling the number of new HIV diagnoses for different levels of coverage of the screening strategy in the Paris metropolitan area.
Methods The strategies will be compared in 18 EDs of Paris metropolitan area during two periods. The start of the intervention strategy will be randomly allocated for each ED following a stepped-wedge cluster randomized trial.
EDs are selected according to the proportion of patients belonging to key populations in the patients they receive (data from two previous studies).
During intervention period, nurses will suggest performing an HIV rapid test to patients belonging to key populations according to the answers to a self-administered questionnaire.
The intervention period will last 3 to 11 months and the control period 0 to 8 months. Patients will participate up to 1 month if a follow-up is needed.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hiv, Nurse's Role
Keywords
Emergency service, Hospital, HIV, Mass screening, Nurses, Prevention and control, Key populations, Targeted screening
7. Study Design
Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
487000 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Nurse-driven HIV screening for key populations+UD
Arm Type
Experimental
Arm Description
Nurse-driven HIV screening for key populations combined with usual physician-directed diagnostic testing (UD)
Arm Title
Physician-directed diagnostic testing alone
Arm Type
Active Comparator
Intervention Type
Procedure
Intervention Name(s)
Nurse-driven HIV screening for key populations combined with usual physician-directed diagnostic testing
Intervention Description
A self-administered questionnaire on HIV exposure factors will be offered to all patients of ages 18-64 able to complete it. This questionnaire will be available in a paper-based format, electronic format on the patient phone or can be conducted verbally by the nurse. According to the answers, the nurses will suggest performing a rapid test to patients belonging to key populations. A finger-stick rapid HIV test will be performed and results will be disclosed by the nurse assisted by a physician if necessary.
If needed, a follow-up visit with an infectious disease specialist will be scheduled within 72 hours.
Intervention Type
Other
Intervention Name(s)
Physician-directed diagnostic testing
Intervention Description
Throughout the intervention, physicians will prescribe HIV tests to patients with HIV-related symptoms, following usual practice.
Primary Outcome Measure Information:
Title
Proportion of new HIV diagnoses among included patients.
Time Frame
At the end of the expected total duration of the inclusion period: 11 months in each ED
Secondary Outcome Measure Information:
Title
Feasibility of the screening strategy and its implementation
Description
Feasibility of the screening strategy and its implementation based on:
proportion of distributed and completed self-administered questionnaires among the patients included and among the patients able to participate who were not known to be HIV positive,
the proportion of rapid tests offered by nurses among patients belonging to key populations,
the proportion of patients screened by nurses among patients who were offered a rapid test and among patients belonging to high-risk groups .
Time Frame
At the end of the expected total duration of the inclusion period: 11 months in each ED
Title
Effectiveness of the screening processes used by the caregivers, particularly the integration of the electronic questionnaire, and used by the patients as well as acceptability
Time Frame
At the end of the expected total duration of the inclusion period: 11 months in each ED
Title
Proportions of patients with a new diagnosis
Description
Proportions of patients with a new diagnosis who had:
a follow up visit with an infectious disease specialist within 1 month,
a CD4 cell count greater or equal to 500 or 350/µL and no HIV-related symptoms,
an acute HIV infection.
Time Frame
At the end of the expected total duration of the inclusion period: 11 months in each ED
Title
Estimation through modelling of the number of new HIV diagnoses for different levels of coverage of the screening strategy in the Paris metropolitan area.
Time Frame
At the end of the expected total duration of the inclusion period: 11 months in each ED
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
64 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
- Patients aged 18 to 64 years and visiting a participating ED for reasons other than a potential exposure to HIV within less than 48 hours
Exclusion Criteria:
- Not applicable
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Judith LEBLANC, RN, PhD
Phone
00 33 1 49 28 22 02
Email
judith.leblanc@aphp.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Anne-Claude CREMIEUX, Md, PhD
Phone
00 33 1 49 28 22 02
Email
anne-claude.cremieux@aphp.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
judith LEBLANC
Organizational Affiliation
Assistance Publique - Hôpitaux de Paris
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Does the Implementation of Nurse-driven HIV Screening for Key Populations in the Emergency Departments Limit Undiagnosed Infections in the Paris Metropolitan Area? DEPIST Trial (ANRS 14055)
We'll reach out to this number within 24 hrs